



Company Presentation April 2021

A subsidiary of **evogene**
DECODING BIOLOGY

Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events, and Canonic Ltd (the "Company") and its parent, Evogene Ltd. ("Evogene"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

A close-up photograph of cannabis buds. The buds are covered in a dense layer of white trichomes, giving them a frosty appearance. Yellow pistils are visible protruding from the buds. The background is blurred, showing more green foliage.

INTRODUCTION

Company Overview

- Canonic was established in early 2019 as a **spin-off from Evogene** (NASDAQ, TASE: EVGN) focusing on medical cannabis
- Canonic has an **exclusive license** to develop cannabis varieties using Evogene's state-of-the-art **computational genomics technology**
- **Distinct advantage to tackle market challenges** by mapping, decoding and stabilizing the cannabis genetics
- **Breeding infrastructure** among the biggest in Israel and unique proprietary knowhow
- First generation varieties expected to produce **premium quality products** to connect the company with the patients and market
- **Product launch expected at early 2022**- the company is evaluating its first-generation varieties with licensed growers and in preparation for commercial cultivation
- Company products expected to be launched under the "**Canonic**" **brand** in Israel followed by the EU and NA with local partners
- Next generation products expected to focus on 2 major medical indications, **pain and inflammation** that are >60% of the medical market*

*Company estimate, based on data published by Israeli Health Ministry regarding number of medical cannabis users in Israel

OUR VISION

Commercialize effective, precise and stable medical cannabis products, based on novel cannabis varieties, for optimized therapeutic impact

We are here because genetics can make cannabis much more effective



Team



Dr. Arnon Heyman
CEO



Dr. Inbal Dangoor
VP R&D



Guy Adler
Product manager & business
development



Ido Zinger
Propagation



Elad Bonjak
Technician



Yoanatan Wegman
Agronomist



Dr. Michi Brog
Plant breeder

Directors and Advisory Board

Board of directors



Ofer Haviv
Chairman of the board
Evogene President & CEO



Raanan Cohen
Business strategy
Former CEO Koor industries



Dorit Kreiner
Finance
Evogene CFO

Advisors




Dr. Yossi Tam
Cannabinoid clinical research
Director, Multidisciplinary Center for
Cannabinoid Research of the Hebrew university



Dr. Yariv Brotman
Plant metabolic pathways
Ben Gurion University & Max Planck
institute of Molecular Plant Physiology



Shai Leviatov
Plant breeding
Commercial varieties breeding for
more than 30 years in top leading
multinational seeds companies




Adv. Itay Rosenfeld
Business strategy
Cannabis entrepreneur and
former BOD member of
Intelicanna (TLV: INTL)



Nirit Elyovich
Marketing strategy
Senior marketing specialist with
over 20 years of B2C experience in
various markets

Global Cannabis Market

Medical cannabis is >60% of the global market



Market Challenges & The Opportunity

THE CHALLENGES



STABILITY

Substantial variations within varieties produce inconsistent products and therefore inconsistent results



YIELD

More active compounds and income per sq foot



SPECIFICITY

Significant knowledge gap prevents matching active compounds to medical indications

THE OPPORTUNITY- With state-of-the-art plant genomic expertise Canonica can solve major market challenges

From Plant Genetics – To Medical Cannabis Products

Plant genetic knowhow is the basis for development of **premium Cannabis varieties**



Premium varieties lead to **novel medical Cannabis products** addressing market challenges



Technology



Proven Capabilities Along The Development Value Chain

The only company in Israel holding computational genomics capabilities and the full plant infrastructure to execute



Large genetic & breeding collections



State of the art data collection tools



State of the art computational genomics



Advanced-breeding facility



Fully equipped labs & tissue culture rooms



Propagation farm



The Genomic Power – Trait Improvement

The potential – improving plant traits through genomic elements

Example- wild corn went through numerous genomic changes before it became a commercial crop. Today corn is the food market basis for the entire world.

The challenge:

How can we connect genes to traits?

How can we shorten the development time?



Wild Maze



Cultured Maze




When Genomics Meets Computational Biology



Computational Genomics

Combining deep scientific knowhow with Big Data and AI technology to tailor the plant genetic for improvement of plant traits and development of unique cannabis products



Big Data & AI transforming Data to Knowhow



Plant genomics database with $>10^9$ data points on >200 plants



Proprietary Cannabis genomic & chemical data on >800 lines from 50 sources




Pre-clinical data



BIG DATA



AI



Cannabis tailored unique database

Gene Rator^{AI}

Computational genomics tools



**MetaYield⁺
Precise⁺**



Canonic Holds Unique Knowhow in Plant Genetics

Controlling genetics ➤ controlling plant traits ➤ improving cannabis type & quality

Plant traits under
development at
Canonic

Inflorescence size

Inflorescence density

Reducing target compound

Disease resistance

Time to flower



Medical effect

Active compounds

Trichome density

Increasing target compound

Plant architecture

PRODUCTS

Variety Families Under Development

MetaYield⁺

Stable enhancement of **total plant** compounds.

Focus on **agronomic** and **consumer** traits.



Increased compounds per plant
[e.g. Increased trichomes prevalence]



Increased compounds per area
[e.g. Dwarf & early flowering]

First product launch expected in 2022

Precise⁺

Stable enhancement of **specific active** compounds

Focus on **therapeutic** traits



Medical indication focus
[e.g. Pain & Inflammation]



Compound profile focus
[e.g. CBG, CBC]

First product launch expected in 2023

MetaYield⁺ : First Commercial Varieties

Canonic expects to commercialize its first varieties during 2022



Variety name- NOA series

High THC

High yield

Big inflorescence

Dense trichomes



Status:
pre-
commercial



**Relevant
market segment:**
T20/C4**



**Expected
launch in Israel:**
early 2022



Target markets:
Israel (\$250M*)
EU (\$500M*)

*Company estimate, based on current market sale prices and data published by Israeli Health Ministry regarding number of medical cannabis users in Israel and by Prohibition Partners in The European Cannabis Report Feb 2020.

** THC 20%, CBD 4%

Precise⁺ : Next Generation Varieties

Product 1



- Indication: Inflammation
- Pre-clinical study: Hadassah medical center
- Status: product development
- Expected launch in Israel: 2023
- Target market size:* Israel \$115M, EU \$300M



Product 2



- Indication: Pain
- Pre-clinical study: Migal research center
- Status: product development
- Expected launch in Israel: 2023
- Target market size:* Israel \$280 M, EU \$750M



*Company estimate, based on current market sale prices and data published by Israeli Health Ministry regarding number of medical cannabis users in Israel and by Prohibition Partners in The European Cannabis Report Feb 2020.

Collaboration With Tikun Olam-Cannbit as Part of Precise+ Product Development

Precise⁺

Stable enhancement of **specific active** compounds

Focus on **therapeutic** traits



Medical indication focus



Compound profile focus



Cannbit, subsidiary of Tikun Olam-Cannbit, and Canonic of Evogene group announce collaboration for the development of novel medical cannabis products

Collaboration to combine the cannabis expertise of both parties, including extensive clinical and related data of Cannbit and leading computational predictive biology capabilities and genomic data of Canonic


Tel-Aviv and Rehovot, Israel – February 24th, 2021 – Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. (TASE: TKUN), a leading medical cannabis company, and Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), focused on the development of medical cannabis products, today announced that they have entered into a collaboration agreement for the development of novel medical cannabis products.

Business model




Cannabis Value Chain

FROM GENOMICS TO PRODUCT



Canonic in the Cannabis Value Chain

Quickly and cost effectively reach the end user, by leveraging proprietary genomic expertise and outsourcing downstream elements of the value chain



Value Creation – Short Term Milestones

2021- pre commercial



◆ **MetaYield** –

- ❖ reach 1st commercial variety;
- ✓ ❖ sign production and distribution agreements in anticipation for commercialization in 2022

- ◆ **Precise** - identify specific lines that exhibit distinct effect in model systems for reducing pain or inflammation


2022- commercial



- ◆ **MetaYield** - commercial launch and initial sales of 1st product in Israel

- ◆ **Precise** - reach 1st commercial variety for reducing pain or inflammation as preparation for commercial launch in 2023

Anticipated Commercial Milestones (5y)



Summary

Cutting-Edge Technology Addressing Market Challenges



Stability



Specificity



Yield



Reduced genetic variation



Diverse extracts for pre-clinical assays



Increased trichome density



Summary

Canonic aims to develop novel varieties through a unique genomic approach and **commercialize medical grade Cannabis**

Product launch expected in 2022

Exclusive access to computational genomics technology

Infrastructure in place – from seed to sale

Commercial partners in place for cultivation, production and distribution (IL)

Leading **academic partnerships** for unique variety development



CANONiC
Cultivated by Science

THANK YOU